Hester Biosciences Ltd Q3 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 30 May 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹2.1K Cr
Company aims to steadily grow the bottom line despite Q3 dip, with targets better than last 2-3 years. Management acknowledges Q3 earnings were disappointing but is confident of recovery and improved performance in upcoming quarters.
From Hester Biosciences Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹2,368
Market Cap
₹2.1K Cr
P/E Ratio
38.7
How does Hester Biosciences Ltd rank in Pharmaceuticals & Biotechnology?
Compare Hester Biosciences Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Hester Biosciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹100 Cr, net profit ₹17 Cr.
Full financials →📊 Revenue & Sales Performance
- →Company aims to steadily grow the bottom line despite Q3 dip, with targets better than last 2-3 years.
- →Focus on expanding vaccine portfolio with new vaccines, including Avian Influenza vaccine launch expected next financial year.
- →Significant growth expected from Petcare division, which showed 105% Q3 growth; emphasis on new product launches and market penetration.
- →Plans to substantially increase health products turnover, potentially exceeding vaccine sales in the coming years.
- →African market, especially Tanzania and Ethiopia, is anticipated to contribute a big leap in revenue in next two quarters and beyond.
- →Government vaccination programs (e.g., PPR, Goat Pox) tender activity expected to continue steadily supporting sales.
- →Capacity utilization: India at ~70% is sufficient for next two years; Africa and Nepal have low utilization but capacity exists for growth.
- →Overall, commitment to quantitative and qualitative efforts for sustained long-term growth, despite short-term challenges.
📈 Profitability & Margins
- →Management acknowledges Q3 earnings were disappointing but is confident of recovery and improved performance in upcoming quarters.
- →There is a clear determination to substantially improve the bottom line.
- →Operational efficiencies and new product introductions are ongoing to drive growth.
- →Focus on expanding vaccine sales and health products, with health products expected to exceed vaccine sales in coming years.
- →African markets, particularly Tanzania and Ethiopia, are expected to contribute to significant growth, potentially changing consolidated financials positively.
- →Petcare division shows strong growth potential despite its current small base.
- →Capacity utilization in India (~70%) is adequate for growth over the next 2 years; international capacities are underutilized, indicating room for scale-up without heavy CAPEX.
- →Management refrains from issuing precise guidance but aims for better-than-past performance based on internal forecasts and budgets.
🏗️ Capital Expenditure Plans
- →Current capacity utilization in India is around 70%, with other countries (Nepal, Africa) much lower (10-20%), indicating enough existing capacity for growth in the next 2 years.
- →No immediate plans for capacity expansion in India as current capacity is sufficient for near-term growth.
- →Company has internal budgets and forecasts ready but refrains from giving explicit guidance on CAPEX or growth.
- →Focus remains on improving profitability and operational efficiency rather than immediate capital expansion.
- →Emphasis on launching new products (e.g., Avian Influenza vaccine) and expanding health products portfolio alongside vaccines, which suggests strategic investment in R&D and product development.
- →Strategic investments focus on market expansion (notably Africa and domestic) and enhancing product mix rather than heavy capital expenditure at this stage.
💰 Fundraising & Capital Structure
- →There is no explicit mention of any current or future fundraising plans through debt or equity in the transcript.
- →The management indicated they have internal budgets and forecasts ready but refrained from giving formal guidance on revenue, growth, or CAPEX.
- →They emphasized operational efficiency improvements and are focusing on steady bottom-line growth and market expansion rather than immediate capital raising.
- →Capacity utilization currently suffices for the next two years, suggesting no urgent need for capacity expansion funding.
- →Overall, the call reflects a cautious approach without specific announcements regarding new debt or equity fundraising.
📋 Order Book & Pipeline
- →The transcript does not explicitly mention the current or expected order book or pending orders in numerical terms.
- →However, it indicates ongoing government tenders, especially for PPR and goat pox vaccines under the National Animal Disease Control Program.
- →Tanzania tenders have been published and awarded; supplies are set to begin.
- →The company is actively participating in international tenders and trade sales across Africa, with expectations of increased business in the coming quarters.
- →There are inquiries for exporting Avian Influenza vaccines to the Middle East and Africa.
- →No material delays reported in vaccine supply to the government, and tendering activities are expected to continue at current levels.
- →Overall, the company expresses confidence in recovering from recent dips and ramping up supplies in the near future.
Key Metrics
Frequently Asked Questions
What were Hester Biosciences Ltd Q3 FY25 results?
Company aims to steadily grow the bottom line despite Q3 dip, with targets better than last 2-3 years. Management acknowledges Q3 earnings were disappointing but is confident of recovery and improved performance in upcoming quarters.
What is Hester Biosciences Ltd share price analysis?
Hester Biosciences Ltd currently shows a neutral. The stock trades at a P/E of 38.7 with a market cap of ₹2,054 Cr. Investors should review the full earnings analysis for detailed insights.
Is Hester Biosciences Ltd planning capital expenditure?
Current capacity utilization in India is around 70%, with other countries (Nepal, Africa) much lower (10-20%), indicating enough existing capacity for growth in the next 2 years.
Keep Hester Biosciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.